[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580887":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":38,"locations":45,"responsibleParty":62,"collaborators":65,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":72,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":33,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":48,"whyStopped":33,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Université de Sherbrooke","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo group","PLACEBO_COMPARATOR","It will be a 12-week treatment phase. The placebo treatment will be administered once daily, at the end of the largest meal.",[13],"Drug: Placebo Oral Tablet",{"label":15,"type":16,"description":17,"interventionNames":18},"Niacin group","ACTIVE_COMPARATOR","It will be a 12-week treatment phase. The treatment will be administered once daily, at the end of the largest meal.",[19],"Drug: Niacin (250mg)",[21,29],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Niacin (250mg)","Niacin will be orally taken once daily with the largest meal. There will be a 3-week escalation period from 250 mg to 750 mg:\n\n* Week 1: 250mg\n* Week 2: 500mg\n* Week 3 to Week 12: 750mg (3 x 250mg caplets)",[15],[27,28],"Nicotinic Acid","Vitamin B3",{"type":22,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"Placebo Oral Tablet","Placebo will be orally taken once daily with the largest meal. There will be a 3-week escalation period from 250 mg to 750 mg:\n\n* Week 1: 250mg\n* Week 2: 500mg\n* Week 3 to Week 12: 750mg (3 x 250mg caplets)",[9],null,[35],{"name":36,"affiliation":5,"role":37},"André Carpentier, MD","PRINCIPAL_INVESTIGATOR",[39],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},"Frédérique Frisch","CONTACT","1-819-346-1110","12394","frederique.frisch@usherbrooke.ca",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Centre de recherche du CHUS","RECRUITING","Sherbrooke","Quebec","J1H 5N4","Canada","CA",{"type":55,"coordinates":56},"Point",[57,58],-71.89908,45.40008,{"lat":58,"lon":57},[61],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},{"type":37,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"André Carpentier","Tenure professor",[66,68],{"name":67,"class":6},"CHU de Quebec-Universite Laval",{"name":69,"class":6},"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","100580887","stimulating-fat-tissue-storage-with-niacin-to-reduce-fat-accumulation-in-the-liver-100580887",false,"NCT06843148","Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.","Stimulating Adipose Tissue Fatty Acid Disposal With Low-dose, Postprandial, Intermittent Niacin for the Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD).","AGL13","Inclusion Criteria:\n\n* aged 20 to 80 years;\n* diagnosed with MASLD, defined as the presence of liver steatosis + abdominal obesity (as defined by the International Diabetes Federation country\u002Fethnic group-specific criteria;\n\nExclusion Criteria:\n\n1\\) Presence of advanced fibrosis using any of the following criteria 1.1 (i.e., ≥ F3 based on liver stiffness \\> 10kPa) using vibration-controlled transient elastography (FibroScan), 1.2 (Index for Liver Fibrosis \\> 2.67) using Fibrosis-4 (FIB-4) which is a calculated score based on age and a combination of lab tests (aspartate aminotransferase \\[AST\\], alanine aminotransferase \\[ALT\\], and platelet count), 1.3 serum ALT \\> 3 times the normal upper limit, 1.4 or signs of portal hypertension. 2) Other hepatic disease. 4) Overt cardiovascular or renal disease, cancer (other than non-melanoma skin cancer), or other uncontrolled medical conditions.\n\n5\\) Any contraindication to MRI. 6) Previous intolerance or allergy to nicotinic acid. 7) Having participated to a research study with exposure to radiation in the last two years before the start of the study.\n\n8\\) Being allergic to eggs 9) Smoking (\\>1 cigarette\u002Fday) and\u002For consumption of \\>2 alcoholic beverages per day.\n\n10\\) Women who are pregnant or breastfeeding.","ALL","20 Years","80 Years",{"count":82,"type":83},36,"ESTIMATED","INTERVENTIONAL",[86],"NA","Metabolic dysfunction-associated steatotic liver disease (MASLD) (aka non-alcoholic fatty liver disease), commonly occurring in individuals with obesity and type 2 diabetes can lead to liver inflammation\u002F fibrosis. MASLD results from fat being disproportionately deposited in the liver.\n\nThe goal of this mechanistic study is to investigate metabolic response in patients aged 20 to 80 years with non-alcoholic fatty liver disease, after niacin (vitamin B3) treatment.\n\nThe main questions it aims to answer are:\n\n* Does Niacin lower the fat deposition in the liver?\n* Does Niacin raise White Adipose Tissue storage of dietary fatty acids?\n\nResearchers will compare Niacin to a placebo (a look-alike substance that contains no drug) to compare the metabolic response.\n\nDuration of study per participant: Up to 28 weeks",[89,90,91],"Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)","Liver Fibrosis\u002FNASH","Non-Alcoholic Steato-Hepatitis (NASH)",[93,94,95,96],"Fatty liver","Niacin","vitamin B3","nicotinic acid","2026-06-30",{"date":99,"type":100},"2026-07-02","ACTUAL",{"date":102,"type":100},"2026-06-22",{"date":104,"type":83},"2030-07",{"name":5,"class":6},1]